Jawad Ahsan
Analyst · Keith Housum with Northcoast Research
Thanks, Luke. Before we move on to our 2020 outlook, I also want to take a moment and say how proud I am of our team. After a tough Q2 last year, our teams faced into the challenges and worked hard to regain ground, proving that we could deliver strong top line growth and margin expansion in 2019. If our finish to the year reinforces anything, it's that Axon has a strong sense of accountability. Our customers are counting on us to deliver life-saving products and our credibility with shareholders is vitally important to us. At our Investor Day in November of 2017, we laid out a three year vision for the company that showed our path to continued strong top line growth, while also turning around our declining margins. We also set a goal for ourselves to be profitable in the body camera and DEMS business with three years, and we achieved that ahead of schedule. Since 2017, our revenues have grown at an annual CAGR of 26% and our EBITDA margins have expanded to 16.5% on an adjusted basis. The body camera business is now profitable and the TASER 7 and Axon Body 3 launches are now behind us. We are heading into 2020 with strong tailwinds on profitability that we intend to use to slingshot our way to the next phase of growth. We have built a high-growth, high margin, high retention $161 million ARR enterprise software business, and we haven't even begun recognizing revenue for Axon Records. Today, we're charting a new path to the company. We have set for ourselves a North Star, that by the end of the decade, we will have achieved the following: First, TASER weapons will be the primary means to stop a threat. Second, AI-enabled body cameras will eliminate the majority of manual report writing. Third, cloud-enabled devices will be the primary means to dispatch officers in the field. And finally, Axon will be a household name by virtue of the transformative value we'll create for society and shareholders. From a financial standpoint, we'll also have built a business that we're targeting to deliver revenue growth of over 20% per year and achieve continued operating leverage with EBITDA margins approaching 30% on an adjusted basis. To get to these outcomes, we see a unique opportunity to accelerate the funding of some of our most promising new growth initiatives. In 2020, we'll invest over $100 million in R&D and new channel growth, excluding stock comp. An example of one such R&D initiative is dispatch. Our goal was to bring dispatch to market in 2020, and that team is tracking so well under the leadership of Josh Pepper that we expect to have our first paying customer live within the first half of this year. This deployment will see Axon displacing a major competitor in the dispatch space. We expect to have a competitive dispatch product in market and widely available by the second half. In terms of channel growth, one of our key initiatives is our investment in federal. In 2018, we hired Richard Coleman from General Dynamics to head up our federal business, and he has led us to some terrific early wins, such as the U.S. Forest Service and the DOJ's Bureau of Alcohol, Tobacco, Firearms and Explosives. We're excited about the prospect of serving that $1.5 billion TAM, and we'll be investing more aggressively in this area going forward. While we're very excited about the momentum we're carrying into 2020, we are not stopping to celebrate. We are instead putting the pedal to the floor, and you can expect us to continue to execute with a high degree of accountability. And with that, operator, let's turn to questions.